<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384812</url>
  </required_header>
  <id_info>
    <org_study_id>DHC-PGE2-2011</org_study_id>
    <nct_id>NCT01384812</nct_id>
  </id_info>
  <brief_title>Prostaglandin E2 in Migraine Suffers Without Aura.</brief_title>
  <official_title>Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of Prostaglandin E2 in Migraine Suffers Without Aura.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Troels Wienecke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that Prostaglandin E2 (PGE2) induces headache and dilatation
      of brain vessels in migraine patients without aura.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache score on a 10-point verbal rating scale (VRS).</measure>
    <time_frame>24 h</time_frame>
    <description>Incidence of headache 0 indicated no headache; 1 indicated a different sensation, pounding or throbbing, but not necessarily painful; 5 indicated moderate headache and 10 indicated worst imaginable headache.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood flow velocity in the middle cerebral artery (VMCA) measured by a Transcranial Doppler (TCD) ultrasonography (2MHz).</measure>
    <time_frame>90 min</time_frame>
    <description>Changes from base line recorded every 10th min. until time 90 min on day 1 and day 2. The infusion takes 25 min from time 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter of superficial temporal artery and radial artery measured by a high resolution ultrasound scanner, C-scan.</measure>
    <time_frame>90 min</time_frame>
    <description>Changes from base line recorded every 10th min. until time 90 min on day 1 and day 2. The infusion takes 25 min from time 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure (MAP).</measure>
    <time_frame>90 min</time_frame>
    <description>Changes from base line recorded every 10th min. until time 90 min on day 1 and day 2. The infusion takes 25 min from time 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography (ECG).</measure>
    <time_frame>90 min</time_frame>
    <description>Changes from base line recorded every 10th min. until time 90 min on day 1 and day 2. The infusion takes 25 min from time 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR).</measure>
    <time_frame>90 min</time_frame>
    <description>Changes from base line recorded every 10th min. until time 90 min on day 1 and day 2. The infusion takes 25 min from time 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-tidal partial pressure of pCO2 (PetCO2).</measure>
    <time_frame>90 min</time_frame>
    <description>Changes from base line recorded every 10th min. until time 90 min on day 1 and day 2. The infusion takes 25 min from time 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous arterial oxygen saturation (SAT)</measure>
    <time_frame>90 min</time_frame>
    <description>Changes from base line recorded every 10th min. until time 90 min on day 1 and day 2. The infusion takes 25 min from time 0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>&quot;Migraine-like&quot; Headache</condition>
  <arm_group>
    <arm_group_label>Isoton sodium chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostin E2 (dinoprostone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dinoprostone</intervention_name>
    <description>intravenous injection 0.4 Î¼gr/kg/min for 25 min</description>
    <arm_group_label>Prostin E2 (dinoprostone)</arm_group_label>
    <other_name>Prostin E2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoton sodium chloride</intervention_name>
    <description>intravenous injection for 25 min</description>
    <arm_group_label>Isoton sodium chloride</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with migraine without aura

        Exclusion Criteria:

          -  Tension type headache more than x 3 per month

          -  Other forms for primary headache

          -  Headache 24 h before the day of the investigation

          -  Migraine 48 h before the day of the investigation

          -  Hypertension

          -  Hypotension

          -  Pregnant/nursing

          -  Daily intake of medication (except oral contraceptives and migraine rescue medicine
             during migraine attack)

          -  Cardiovascular or central nervous system (CNS) disease

          -  Drug/alcohol abuse

          -  Psychiatric disease

          -  Asthma or any other lung diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Troels Wienecke, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>November 8, 2011</last_update_submitted>
  <last_update_submitted_qc>November 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Troels Wienecke</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

